Biotechnology

BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024

September 9, 2024 1:20 AM

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV) BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising efficacy data in combination with KEYTRUDA® (pembrolizumab) with partial responses in relapsed and refractory advanced melanoma and leiomyosarcoma patients. Favorable safety profile with minimal adverse events and no dose-limiting toxicities. Lund,...

Read more

Medical University of Graz Selects the HALO AP(R) Digital Pathology Platform to Deliver Comprehensive Diagnostics

September 6, 2024 8:00 AM

The Diagnostics & Research Institute for Pathology at the Medical University of Graz, a leader in personalized patient care and one of the largest hospitals in Austria, has selected the HALO AP® digital pathology platform from Indica Labs to deliver primary diagnostics. The enterprise digital pathology platform was selected alongside Aperio GT 450 scanners from Leica Biosystems for quality, performance, functionality, and usability. The...

Read more

Tanvex BioPharma Forging Strategic Alliance With Bora Pharmaceuticals

September 5, 2024 12:05 PM

Combining Tanvex's biosimilar development expertise and U.S. FDA-licensed commercial-scale facility in San Diego, California, with Bora's extensive global CDMO capabilities, the alliance aims to provide comprehensive solutions to biologics CDMO customers around the world. SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Tanvex BioPharma ("Tanvex" or the "Company"), a contract development and manufacturing organization (CDMO) for biologics and a...

Read more

Cambridge Isotope Laboratories, Inc. Expands 13C Production Capacity With North Star Project

September 5, 2024 9:00 AM

TEWKSBURY, MA / ACCESSWIRE / September 5, 2024 / Cambridge Isotope Laboratories, Inc. (CIL), the global leader in 13Cand 13C urea production, is excited to announce the startup of its North Star project, significantly increasing the company's production capabilities. CIS Aerial CIS Aerial The North Star project commenced in mid-2020 as the world's largest 13C production cascade. After the complex build of phase one finished in March 2024, CIL...

Read more

Prolocor and Slingshot Biosciences Announce Publication of 'Assessing Prognosis by Quantifying FcγRIIa on Fixed Platelets' in Bioanalysis

September 5, 2024 8:00 AM

The Prolocor pFCG® test measures the expression of a specific protein on the platelet surface which this study demonstrates is a reliable prognostic tool to help assess the risk of thrombosis (a key cause of heart attack & stroke) and inform clinical decision making. This novel test is performed on fixed platelets and uses TruCytes cell mimics (produced by Slingshot Biosciences) as an internal control to improve precision, accuracy, and linear...

Read more

Moolec Confirms US Harvest and Promising Yields for Plant-Grown Products GLASO(TM) and Piggy Sooy(TM) in October

September 5, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / September 5, 2024 / Moolec Science SA (NASDAQ:MLEC) ("The Company", "Moolec"), a science-based food ingredient company, announced today the harvest confirmation of US campaigns for genetically engineered plant-grown products GLASO™ and Piggy Sooy™ during October 2024. GLASO™ and Piggy Sooy™ US Harvest Announcement GLASO™ (gamma-linolenic acid -GLA- in safflower oil) campaign located in Idaho consists of 600 planted...

Read more

Adolore BioTherapeutics Announces Issuance of First Japanese Patent Covering CA8* Long-Acting Local Analgesic Therapies to Treat Chronic Pain

September 4, 2024 8:00 AM

Patent and novel, potent CA8* nonopioid analgesic licensed by Adolore BioTherapeutics from the University of Miami Company is advancing development of rdHSV-CA8* gene therapy delivered intracellularly for the treatment of chronic osteoarthritis (OA) knee pain toward an IND with NIH/NINDS UH3 HEAL funding up to and including the First-in-Human clinical study DELRAY BEACH, FL / ACCESSWIRE / September 4, 2024 / Adolore BioTherapeutics ("Adolore" or...

Read more

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 3, 2024 9:00 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter ("OTC") drug development programs, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel. Presentation Date:...

Read more

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing

September 3, 2024 9:00 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Sandy Prietto has joined the Company as Vice President of Marketing. Ms. Prietto brings many years of medical device marketing experience including successful new product launches at Endologix and Edwards Lifesciences. "In addition to the wealth of marketing experience and...

Read more

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

August 29, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has entered into definitive agreements, providing the Company with aggregate gross proceeds of $5 million, for the issuance and sale of an aggregate of...

Read more

FluoGuide A/S Publishes Interim Report for the Period January - June 2024

August 29, 2024 3:05 AM

KØBENHAVN, DENMARK / ACCESSWIRE / August 29, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 29 August 2024 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 30 June 2024. The Q2 report is available as an attached document to this press release and on FluoGuide's website. In Q2 2024, the Company successfully completed a directed share issue, raising proceeds SEK 60 million to support the...

Read more

Vicore Announces Presentations at the European Respiratory Society Congress 2024

August 29, 2024 2:10 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / August 29, 2024 / Vicore Pharma Holding (STO:VICO) Sessions at the upcoming ERS include an oral presentation of additional Phase 2a AIR trial data of buloxibutid in IPF Additional presentations include preclinical and translational data reflecting the impact of buloxibutid's upstream mechanism of action Vicore will additionally present on aspects of the Phase 2b ASPIRE trial designed to maximize patient...

Read more

BioInvent International AB: Interim Report January-June 2024

August 29, 2024 2:10 AM

LUND, SWEDEN / ACCESSWIRE / August 29, 2024 / BioInvent International (STO:BINV) "The presentation of promising results from our two lead drug candidates at the ASCO Annual Meeting showcased their potential as first-in-class immunomodulatory agents and kicked off a data-rich period for BioInvent where we expect to report results from all six of our clinical programs." - Martin Welschof, CEO of BioInvent. EVENTS IN THE SECOND QUARTER • (R)...

Read more

Hemogenyx Pharmaceuticals PLC Announces Presentation at CBD S&T Conference

August 28, 2024 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 2024 Chemical and Biological Defense Science & Technology ("CBD S&T") Conference, which will be held on December 2-5, 2024, in Fort Lauderdale, FL. The Company competed for a presentation slot and was invited to present its work on its proprietary Chimeric Bait...

Read more

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

August 27, 2024 2:30 PM

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received Investigational Review Board ("IRB") approval of the PF614-MPAR-102 protocol, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 capsule...

Read more

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

August 27, 2024 8:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced receipt of a $14 million multi-year grant from the NIH and National Institute on Drug Abuse (NIDA) for the continued development of PF614-MPAR, an abuse-deterrent opioid with overdose protection that received...

Read more

Indica Labs and Paige Forge Strategic Partnership to Expand Integrated AI for Anatomic Pathology Labs

August 27, 2024 8:00 AM

ALBUQUERQUE, NM and NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Indica Labs, a leading provider of computational pathology software and Paige, a leader in next-generation AI technology have formed a non-exclusive partnership aimed at integrating Paige's Diagnostic AI models into Indica's robust Anatomic Pathology workflow management software, HALO AP®. This will include Paige's pan-cancer AI application developed using Paige's foundation model...

Read more

First-of-Its-Kind Study Characterizing the Mechanism of Template Switching With Ultraprocessive Reverse Transcriptase Enzymes

August 27, 2024 7:00 AM

BRANFORD, CT / ACCESSWIRE / August 27, 2024 / A new study demonstrates a significant advancement in our understanding of the template switching mechanism of reverse transcriptases (RTs) that is widely adopted to streamline RNA sequencing library preparation. The paper, Characterization and implementation of the MarathonRT template-switching reaction to expand the capabilities of RNA-Seq, just published in the RNA Society journal RNA, details the...

Read more

FluoGuide Appoints Jens Ellrich as Chief Medical Officer

August 26, 2024 3:20 AM

KØBENHAVN, DENMARK / ACCESSWIRE / August 26, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark - FluoGuide A/S ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces the appointment of Jens Ellrich as Chief Medical Officer, effective November 1, 2024. Jens Ellrich, a German physician and medical scientist, brings over 30 years of extensive experience in translational neuroscience, medical devices,...

Read more

Ondine Biomedical Inc - Steriwave in all British Columbia Health Authorities

August 23, 2024 2:00 AM

VANCOUVER, BC / ACCESSWIRE / August 23, 2024 / Ondine Biomedical Inc. (LON:OBI), a leading provider of light-activated antimicrobial technology to prevent and treat hospital infections, is pleased to announce that Steriwave® nasal decolonization is now being used in all five of British Columbia's health authorities. This deployment signals Ondine's increasingly strong presence across the Canadian healthcare system. As of 21 August 2024, the...

Read more